Improved Earnings Required Before China Shineway Pharmaceutical Group Limited (HKG:2877) Stock's 27% Jump Looks Justified

Simply Wall StOct 18 18:14 ET

China Shineway Pharmaceutical Group's (HKG:2877) Five-year Earnings Growth Trails the 12% YoY Shareholder Returns

Simply Wall StSep 25 18:05 ET

SHINEWAY PHARM: 2024 Interim Report

HKEXSep 19 05:23 ET · Announcements

China Shineway Pharmaceutical Group Limited Goes Ex Dividend Tomorrow

Seeking AlphaSep 10 09:02 ET

Huaxing Securities: Reiterate a "buy" rating on shineway pharm, with the target price lowered to 18 Hong Kong dollars.

Huaxing Securities released a research report stating that it reiterated a 'buy' rating for Shineway Pharm (02877) with a target price of HKD 18, down from HKD 19.3. The bank believes that Shineway Pharm's valuation multiple should be at least equal to comparable companies, due to its robust growth prospects and potential value reevaluation. The report mentioned that the company's revenue in the first half of the year declined year-on-year due to a high base in the previous year, but its net income achieved rapid growth. In the first half of the year, it achieved a revenue of CNY 2.086 billion, a 13% YoY decrease; net income of CNY 0.626 billion, a 28% YoY increase. In addition, the company's net cash per share is close to the stock price, maintaining a high dividend payout ratio.

新浪港股Sep 4 04:53 ET

There's No Escaping China Shineway Pharmaceutical Group Limited's (HKG:2877) Muted Earnings

Simply Wall StAug 30 20:19 ET